
|Podcasts|September 23, 2021
The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics
Author(s)Morgan Petronelli
This episode highlights findings from an investigative study exploring the molecular targeting of biologics for psoriasis, the IL-17 drug class, how bimekizumab is different, plus more.
Advertisement
This episode highlights findings from an investigative study exploring the molecular targeting of biologics for psoriasis, as well as discusses the interleukin(IL)-17 class of biologics, how this class compares to other classes such as IL-23 and TNFα, and how bimekizumab (UCB) sets itself apart from other biologics in the pipeline for psoriasis.
Advertisement
Latest CME
Advertisement
Advertisement









